Phase I trial of SAR 113244, an anti-CXCR5 monoclonal antibody, in patients with systemic lupus erythematosus.

Trial Profile

Phase I trial of SAR 113244, an anti-CXCR5 monoclonal antibody, in patients with systemic lupus erythematosus.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Oct 2012

At a glance

  • Drugs SAR-113244 (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Oct 2012 Profile title is not an official study title
    • 30 Oct 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top